Brugada R
Section of Cardiology, Baylor College of Medicine, Houston, Texas 77030, USA.
Am J Cardiol. 2000 Nov 2;86(9A):28K-33K. doi: 10.1016/s0002-9149(00)01289-3.
Cardiology has participated in the new developments in molecular biology and the impact of the Human Genome Project. In these last few years, we have observed how the research in human physiology and journal publications have been focusing on the most basic molecular level. Clinicians have likely been having trouble keeping up with the new developments and, more importantly, with the highly publicized discoveries trying to discern what is research and what can already be applied at the bedside. Molecular biology has just started, and there is no doubt that it will have a tremendous impact in the diagnosis, prevention, and therapy of most diseases, including sudden death and cardiac arrhythmia. In the last few years, we have seen new data in the field of genetics and arrhythmia that are already shaping our approach to an inherited disease. Routine clinical tests are not yet available, mainly due to the lack of sufficiently powerful technology, but with the pace of evolution at this turn of the millennium, we can certainly assume that such testing is just a matter of time.
心脏病学已经参与到分子生物学的新发展以及人类基因组计划的影响之中。在过去的几年里,我们已经观察到人类生理学研究和期刊出版物是如何聚焦于最基本的分子层面的。临床医生可能在跟上这些新发展方面存在困难,更重要的是,在跟上那些备受关注的发现方面存在困难,他们试图辨别哪些是研究成果,哪些已经可以应用于临床。分子生物学才刚刚起步,毫无疑问,它将对包括猝死和心律失常在内的大多数疾病的诊断、预防和治疗产生巨大影响。在过去几年里,我们在遗传学和心律失常领域看到了新的数据,这些数据已经在塑造我们对一种遗传性疾病的处理方法。常规临床检测目前还不可用,主要是由于缺乏足够强大的技术,但在这个千禧年之交的发展速度下,我们当然可以认为这样的检测只是时间问题。